Apixaban Dosing and Initiation
Stroke Prevention in Non-Valvular Atrial Fibrillation
Start with apixaban 5 mg twice daily for most patients with non-valvular atrial fibrillation. 1, 2
Dose Reduction Criteria
Reduce to 2.5 mg twice daily ONLY if the patient has at least TWO of the following three characteristics: 1, 3, 2
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
This dose reduction requirement is critical—having only one criterion does NOT warrant dose reduction. The evidence shows that inappropriate underdosing (reducing dose when only one criterion is present) is a common error that exposes patients to preventable strokes 4. The ARISTOTLE trial demonstrated that apixaban 5 mg twice daily was superior to warfarin for stroke prevention (HR 0.79,95% CI 0.66-0.95) with significantly lower major bleeding (2.13% vs 3.09% per year) 5.
Renal Function Considerations
For patients with end-stage renal disease on dialysis, the standard dosing applies (5 mg twice daily, or 2.5 mg twice daily if meeting the two-out-of-three criteria above) 2. While clinical trials did not enroll dialysis patients, pharmacokinetic data support these doses 2.
Do not use apixaban in patients with severe hepatic impairment (Child-Pugh C). 2
Acute Deep Vein Thrombosis and Pulmonary Embolism
For acute DVT or PE treatment, initiate apixaban 10 mg twice daily for the first 7 days, then reduce to 5 mg twice daily. 2
This regimen eliminates the need for parenteral anticoagulation bridging—a major advantage over warfarin. The AMPLIFY trial demonstrated this approach was as effective as conventional enoxaparin-warfarin therapy with significantly lower major bleeding 6, 7.
No dose adjustment is needed based on renal function for VTE treatment, even in patients with end-stage renal disease on dialysis 2.
Extended Secondary Prevention of Recurrent VTE
After completing at least 6 months of anticoagulation for DVT/PE, use apixaban 2.5 mg twice daily for extended prevention of recurrence. 2
The AMPLIFY-EXT trial showed that this reduced dose (2.5 mg twice daily) effectively prevented recurrent VTE without increasing major bleeding compared to placebo 6. Notably, a recent trial in cancer patients demonstrated that this reduced dose (2.5 mg twice daily) was noninferior to full-dose (5 mg twice daily) for preventing recurrent VTE while causing significantly less clinically relevant bleeding 8.
Critical Dosing Pitfalls to Avoid
The most common error is inappropriate dose reduction in atrial fibrillation patients. Studies show that approximately 20% of patients receive incorrect doses, with underdosing more frequent than overdosing 4. Remember:
- One criterion alone (age ≥80, weight ≤60 kg, OR creatinine ≥1.5) = use 5 mg twice daily
- Two or more criteria = use 2.5 mg twice daily
Never discontinue apixaban abruptly without bridging to another anticoagulant unless there is pathological bleeding 2. The FDA requires a black box warning because stroke clustering occurs after discontinuation 5.
Switching Between Anticoagulants
When switching FROM warfarin TO apixaban: Stop warfarin and start apixaban when INR <2.0 2
When switching FROM apixaban TO warfarin: Discontinue apixaban and begin both parenteral anticoagulation and warfarin simultaneously at the time of the next scheduled apixaban dose. Stop the parenteral agent when INR reaches therapeutic range 2
When switching between apixaban and other oral anticoagulants (non-warfarin): Simply start the new agent at the time the next dose of the previous agent would have been taken 2
Special Populations
For patients aged 75-80 years with moderate renal impairment (CrCl 30-50 mL/min), gastritis, or other bleeding risk factors, the 2024 ESC guidelines suggest considering dose reduction to 110 mg twice daily for dabigatran, but no specific dose reduction is recommended for apixaban unless the two-out-of-three criteria are met 3.
The 2024 guidelines emphasize that reduced-dose DOAC therapy should not be used unless patients meet DOAC-specific criteria to prevent underdosing and avoidable thromboembolic events 3.